Conference Coverage
Conference Coverage
Abatacept reduced rates of progression to RA, phase 2b trial finds
The study was conducted at 28 sites in the United Kingdom and 3 in The Netherlands.
Conference Coverage
Chest pain with long COVID common but undertreated
“Our current analysis indicates that chest pain continues on for years in many individuals, suggesting that COVID-related chest pain may be...
Conference Coverage
Telitacicept shows efficacy, safety in methotrexate-resistant RA
The investigational drug’s ACR 20 response rate was typical for RA biologic treatments, and the trial’s Chinese patient population didn’t include...
Conference Coverage
More evidence of better outcomes with 120–mm Hg BP target
“We are doing very badly in terms of implementation. There is a big gap between science and what’s happening in the real world.”
Latest News
FDA OKs symplicity renal denervation system for hypertension
The Symplicity Spyral system provides a catheter-based approach to denervate the renal arteries using radiofrequency energy.
Latest News
Single injection reduces blood pressure for 6 months: KARDIA-1
Zilebesiran is a subcutaneous RNA interference therapeutic that binds with high affinity to the hepatic asialoglycoprotein receptor, bringing...
Conference Coverage
Avoid adding to minority stress when treating headache in LGBTQIA+ patients
To address headache in LBGTQIA+ patients, inclusive behavior can set the stage of collaboration toward control.
Conference Coverage
Promising first results with DNA editing to lower LDL
The first in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial...
Conference Coverage
Novel blood test can detect RA
An experimental assay detects epigenetic features within the unique patterns and sizes of cell-free DNA found in blood, but is it better than...
Conference Coverage
Split-dose methotrexate speeds RA response over single dose
Compared with a single dose, more patients in the split-dose group had improved disease activity at 16 weeks, and fewer needed additional DMARDs,...
Conference Coverage
IV secukinumab, alternative to self-injections, reaches primary endpoints in PsA, axSpA
Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy versus placebo in treating psoriatic arthritis and...